Loading..

Natera, Inc. (NTRA) Report Analysis

Corporate Events

Negative

Hagens Berman, National Trial Attorneys, Encour...

2022-06-17 16:49:00

Hagens Berman urges Natera, Inc. investors who suffered significant losses and wish to lead the securities fraud case to submit your losses no...

Neutral

Natera, Inc. Presents at Goldman Sachs 43rd Ann...

2022-06-17 05:39:00

Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM. Venue: Terranea Resort, Rancho Palos Ve...

Negative

Levi & Korsinsky, LLP Notifies Natera, Inc. Inv...

2022-06-09 09:45:00

Levi & Korsinsky, LLP notified investors in Natera, Inc. of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover ...

Neutral

Natera, Inc. Presents at The 2022 ASCO Annual M...

2022-05-31 17:02:00

Natera, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-06-2022 08:00 AM. Venue: McCormick Place, Chicago, Illinois, United States.

Negative

Bronstein, Gewirtz & Grossman, Llc Reminds Inve...

2022-05-31 16:51:00

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companie...

Negative

Natera, Inc. Announces Executive Changes

2022-05-24 12:03:00

Natera, Inc. announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will se...

Positive

Natera, Inc. Revises Financial Guidance for the...

2022-05-05 20:05:00

Natera, Inc. revised financial guidance for the year 2022. The company increased 2022 revenue guidance from $770-790 million to $790-810 million.

Neutral

Natera, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-05-02 12:03:00

Natera, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Natera, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-05-02 12:03:00

Natera, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022

Negative

Kessler Topaz Meltzer & Check, LLP Files Securi...

2022-04-28 00:37:00

Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit in the United States District Court for the Western District of...

Positive

Natera Announces Definitive Study to Evaluate t...

2022-04-26 11:33:00

Natera, Inc. announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world, prospective, multi-center cl...

Positive

Natera, Inc. Announces the Results of Large, Re...

2022-04-19 11:33:00

Natera, Inc. announced the results of a large, real-world study demonstrating a high yield rate for positive genetic findings with its Renasig...

Negative

Natera, Inc. Announces Resignation of Todd Cozz...

2022-04-15 10:41:00

Natera, Inc. announced that on April 8, 2022, Todd Cozzens notified the Board of Directors of the Company of his intention to resign as a memb...

Neutral

Natera, Inc. - Shareholder/Analyst Call

2022-04-13 20:00:00

2022 Annual Meeting of Stockholders

Positive

Natera, Inc. to Present Data from the Beatrice ...

2022-04-11 11:33:00

Natera, Inc. announced that it will present new data relating to its tumor-informed molecular residual disease (MRD) test, Signatera™, at the ...

Neutral

Natera, Inc. Presents at AACR Annual Meeting 20...

2022-04-11 00:00:00

Natera, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 . Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Positive

Natera Publishes Valid Study Results for Prospe...

2022-04-07 11:33:00

Natera, Inc. announced the publication of the VALID study1, showcasing its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test in asses...

Negative

Natera, Inc. Announces Management Changes

2022-04-06 11:33:00

Natera, Inc.  announced Michael Olymbios, M.D., medical director of heart transplantation, and David Ross, M.D., medical director of lung tran...

Positive

Natera, Inc. Announces Publication Highlighting...

2022-04-01 11:33:00

Natera, Inc. announced the results of a study1 to examine both total and donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipient...

Neutral

Blood Profiling Atlas in Cancer, BLOODPAC Summ...

2022-03-29 11:00:00

Blood Profiling Atlas in Cancer, BLOODPAC Summit 2022, Mar 31, 2022.

Neutral

Natera, Inc. Presents at BLOODPAC Summit 2022, ...

2022-03-29 11:00:00

Natera, Inc. Presents at BLOODPAC Summit 2022, Mar-31-2022 .

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Neutral

Natera, Inc. Presents at SLAS 2022 Internationa...

2022-02-04 15:50:00

Natera, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-06-2022 08:30 AM. Venue: Boston Convention and Exhibition Cent...

Neutral

American Association For Cancer Research, AACR ...

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Cent...

Neutral

Society for Laboratory Automation & Screening, ...

2021-12-28 18:17:00

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022. Venue: Bo...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Positive

Natera, Inc. Presents New Signatera™ MRD Data i...

2021-12-09 14:03:00

Natera, Inc. announced its new findings presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, ...

Neutral

Natera, Inc. Presents at Piper Sandler 33rd Ann...

2021-11-22 15:06:00

Natera, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Negative

Lieff Cabraser Files Negligence Lawsuit Against...

2021-11-19 15:18:00

The law firm of Lieff Cabraser Heimann & Bernstein, LLP, announced the filing of a lawsuit against Natera, Inc. alleging negligence, among oth...

Positive

American Journal of Obstetrics and Gynecology A...

2021-11-19 14:00:00

Natera, Inc. announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Ob...

Positive

Medicare Publishes Final Local Coverage Determi...

2021-11-11 16:52:00

Natera, Inc. announced that the CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for p...

Neutral

Natera, Inc. Provides Earnings Guidance for the...

2021-11-04 20:16:00

Natera, Inc. provided earnings guidance for the year 2021. For the year, the company anticipates 2021 total revenue of $615 million to $625 million.

Neutral

Natera, Inc., Q3 2021 Earnings Call, Nov 04, 2021

2021-10-28 12:33:00

Natera, Inc., Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Natera, Inc. to Report Q3, 2021 Results on Nov 04, 2021

2021-10-28 12:33:00

Natera, Inc. announced that they will report Q3, 2021 results After-Market on Nov 04, 2021

Positive

Natera, Inc. Expands Organ Health Business With...

2021-10-18 12:33:00

Natera, Inc. announced the launch and availability of its Prospera donor-derived cfDNA (dd-cfDNA) transplant assessment test for lung transpla...

Positive

Natera, Inc. Announces New Publication Validati...

2021-10-11 12:33:00

Natera, Inc. announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-info...

Positive

Natera Announces Completion of the Largest Pros...

2021-10-06 12:33:00

Natera, Inc. announced the completion of the VALID Study (Validation for Allograft Lungs Implementing Donor-derived cell-free DNA) for Prosper...

Neutral

Volpara Health Technologies Limited to Collabor...

2021-09-29 23:27:00

Volpara Health Technologies Limited has entered into a collaboration agreement with Natera, Inc.to bring Natera's Empower Hereditary Cancer Te...

Neutral

Natera, Inc. Presents at Longwood Healthcare Le...

2021-09-28 18:44:00

Natera, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 03:40 PM. Speakers: Paul R. Billings, Chief Medical Officer & Sen...

Neutral

Longwood Fund, Longwood Healthcare Leaders Conf...

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Positive

Natera, Inc. Releases New Clinical Data at ESMO...

2021-09-17 12:33:00

Natera, Inc. announced new data being presented by the company and its collaborators on the use of the Signatera® personalized molecular resid...

Neutral

Natera, Inc. has filed a Shelf Registration in ...

2021-09-10 00:00:00

Natera, Inc. has filed a Shelf Registration in the amount of $65.539914 million. Security Name: Common Stock Securities Offered: 545,893

Positive

Natera, Inc. Launches Prospera™ Kidney with Qua...

2021-09-09 12:33:00

Natera, Inc. announced the launch of Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values — the q...

Neutral

Natera's Signatera Test Selected for NRG Oncolo...

2021-09-07 10:03:00

Natera, Inc. announced an agreement with NRG Oncology, a National Cancer Institute (NCI)-funded group, to use the Signatera personalized molec...

Positive

Natera Announces the Validation and Launch of t...

2021-08-31 12:30:00

Natera, Inc. announced the validation and clinical availability of its Prospera Heart transplant assessment test for heart transplant recipien...

Neutral

Natera, Inc. Presents at European Society for M...

2021-08-23 12:06:00

Natera, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Par...

Neutral

Natera, Inc. Presents at Morgan Stanley 19th An...

2021-08-10 13:03:00

Natera, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 11:45 AM. Venue: New Windsor, United States. Spe...

Neutral

Robert W. Baird & Co. Incorporated, Baird Globa...

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Natera, Inc. Presents at Baird Global Healthcar...

2021-08-10 13:03:00

Natera, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 03:45 PM. Speakers: Steve Chapman, CEO, President & Director.

Neutral

Natera, Inc. Presents at Canaccord Genuity 41st...

2021-08-07 06:43:00

Natera, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 08:30 AM. Speakers: Michael Brophy, Chief Financial Officer.

Positive

Natera, Inc. Increases Earnings Guidance for th...

2021-08-05 20:05:00

Natera, Inc. increased earnings guidance for the full year of 2021. For the year, the company increased revenue guidance from $550 million to ...

Positive

Natera Announces Use of Signatera® as Companion...

2021-08-04 13:03:00

Natera, Inc. announced that the first patient has been screened in a new phase III trial that uses its personalized, tumor-informed molecular ...

Neutral

Natera, Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-29 13:03:00

Natera, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Natera, Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-29 13:03:00

Natera, Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021

Positive

Natera,Inc Announces New Peer-Reviewed Paper Pu...

2021-07-28 13:03:00

Natera,Inc announced a new peer-reviewed paper published in Gastroenterology validating its personalized and tumor-informed molecular residual...

Neutral

Natera, Inc. Presents at Wells Fargo 2021 Virtu...

2021-07-22 14:24:00

Natera, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 11:20 AM. Speakers: Michael Brophy, Chief Financial Officer.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 V...

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Negative

Natera, Inc. has completed a Follow-on Equity O...

2021-07-21 00:00:00

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $508.5 million. Security Name: Common Stock Security Type: Common ...

Negative

Certain Common Stock of Natera, Inc. are subjec...

2021-07-21 00:00:00

Certain Common Stock of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Common Stock will be under lockup for 61 ...

Negative

Certain Options of Natera, Inc. are subject to ...

2021-07-21 00:00:00

Certain Options of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Options will be under lockup for 61 days start...

Negative

Certain Restricted Stock Units of Natera, Inc....

2021-07-21 00:00:00

Certain Restricted Stock Units of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Restricted Stock Units will b...

Negative

Natera, Inc. has filed a Follow-on Equity Offer...

2021-07-20 00:00:00

Natera, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Security Name: Common Stock Security Type: Common Stock

Neutral

Natera, Inc. Provides Preliminary Earnings Guid...

2021-07-19 12:46:00

Natera, Inc. provided preliminary earnings guidance for the second quarter ended June 30, 2021. Total revenues for the second quarter of 2021 ...

Positive

Natera, Inc. Presents New Data on Personalized ...

2021-07-02 15:00:00

Natera, Inc. announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at t...

Negative

Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’S Attorneys, Deadline Approaching in Securities Class Action

2022-06-17 16:49:00

Hagens Berman urges Natera, Inc. investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now. Class Period: Feb. 26, 2020 – Apr. 19, 2022, Lead Plaintiff Deadline: June 27, 2022. Natera, Inc. Securities Fraud Class Action: Defendants have repeatedly claimed that its screening test for kidney transplant failure (“Prospera”) was superior to competitors’ tests and that its non-invasive prenatal test (“Panorama”) was reliable. According to the complaint, Defendants misrepresented or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants’ false and misleading claims about Natera’s technology, the company was exposed to substantial legal and regulatory risks; and, (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth. On Jan. 1, 2022, The New York Times reported that positive results for genetic disorders such as DiGeorge and Prader-Willi syndromes when using Natera’s test are incorrect more than 80% of the time. On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama. On Mar. 14, 2022, a federal jury found that Natera intentionally and willfully misled the public by utilizing false advertisements to market Prospera as being more effective than CareDx’s competing AlloSure test. Whistleblowers: Persons with non-public information regarding Natera should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

Neutral

Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM

2022-06-17 05:39:00

Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Negative

Levi & Korsinsky, LLP Notifies Natera, Inc. Investors of a Class Action Lawsuit

2022-06-09 09:45:00

Levi & Korsinsky, LLP notified investors in Natera, Inc. of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Natera investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive. The filed complaint alleges that defendants made false statements and/or concealed that: the Company's non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; the Company's screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; as a result of defendants' false and misleading claims about Natera's technology, the Company was exposed to substantial legal and regulatory risks; Natera relied upon deceptive sales and billing practices to drive its revenue growth; and as a result of the foregoing, defendants' statements about the company's business, operations, and prospects lacked a reasonable basis.

Neutral

Natera, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-06-2022 08:00 AM

2022-05-31 17:02:00

Natera, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-06-2022 08:00 AM. Venue: McCormick Place, Chicago, Illinois, United States.

Negative

Bronstein, Gewirtz & Grossman, Llc Reminds Investors That A Class Action Lawsuit Has Been Filed Against IIPR, NTRA & CS

2022-05-31 16:51:00

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Class Period: May 7, 2020 - April 13, 2022. The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) that Innovative Industrial Properties' focus is to be a cannabis company lender rather than a real estate investment trust (REIT); (2) that the true values of Innovative Industrial Properties' properties are significantly lower than Innovative Industrial Properties represents; (3) existential issues in its top customers; (4) that as a result, its top customers may not be able to continue making payments to Innovative Industrial Properties and Innovative Industrial Properties would face significant issues replacing these customers; and (5) that as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Class Period: February 26, 2020 - April 19, 2022. The complaint alleges that, throughout the Class Period, the Defendants misrepresented and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants’ false and misleading claims about Natera’s technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis. Class Period:March 19, 2021 - March 25, 2022. The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Credit Suisse had deficient disclosure controls and procedures and internal control over financial reporting; (ii) Credit Suisse’s practice of lending money to Russian oligarchs subject to U.S. and international sanctions created a significant risk of violating rules pertaining to those sanctions and future sanctions; (iii) the foregoing conduct subjected the Company to an increased risk of heightened regulatory scrutiny and/or enforcement actions; (iv) the Securitization Deal concerned loans that Credit Suisse made to Russian oligarchs previously sanctioned by the U.S.; (v) the purpose of the Securitization Deal was to offload the risks associated with these loans and mitigate the impact on Credit Suisse of sanctions likely to be implemented by Western nations in response to Russia’s invasion of Ukraine; (vi) Credit Suisse’s request that non-participating investors destroy documents related to the Securitization Deal was intended to conceal the Company’s noncompliance with U.S. and international sanctions in its lending practices; (vii) the foregoing, once revealed, was likely to subject the Company to enhanced regulatory scrutiny and significant reputational harm; and (viii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Negative

Natera, Inc. Announces Executive Changes

2022-05-24 12:03:00

Natera, Inc. announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine. Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes in solid tumors and in developing novel therapeutics to improve survival, with a particular focus in breast cancer. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium. Dr. Liu received her B.A. from Princeton University, her M.D. from Jefferson Medical College and completed her residency and hematology/oncology fellowship at Georgetown University Medical Center. In her new position as CMO, Dr. Liu will succeed Dr. Alexey Aleshin, who was recently appointed Natera's general manager of early cancer detection.

Positive

Natera, Inc. Revises Financial Guidance for the Year 2022

2022-05-05 20:05:00

Natera, Inc. revised financial guidance for the year 2022. The company increased 2022 revenue guidance from $770-790 million to $790-810 million.

Neutral

Natera, Inc., Q1 2022 Earnings Call, May 05, 2022

2022-05-02 12:03:00

Natera, Inc., Q1 2022 Earnings Call, May 05, 2022

Neutral

Natera, Inc. to Report Q1, 2022 Results on May 05, 2022

2022-05-02 12:03:00

Natera, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022

Negative

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Natera, Inc

2022-04-28 00:37:00

Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit in the United States District Court for the Western District of Texas against Natera, Inc. (“Natera”) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the “Class Period”). This action is captioned John Harvey Schneider v. Natera, Inc., et al., Case No. 1:22-cv-00398. Natera produces and markets a non-invasive prenatal test (NIPT), called “Panorama,” and a screening test for kidney transplant failure, called “Prospera.” Throughout the Class Period, Defendants repeatedly assured investors that Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera’s growth was driven by its superior technology and customer experience. Investors, however, began to learn the truth on January 1, 2022, when The New York Times published a detailed report calling into question the accuracy of certain prenatal tests manufactured by Natera and other diagnostic testing companies. Among other things, The New York Times reported that Natera’s positive results for several genetic disorders were incorrect more than 80% of the time. On this news, the price of Natera common stock fell $5.35 per share, or approximately 6% over two trading days, from a close of $93.39 per share on December 31, 2021, to close at $88.04 per share on January 4, 2022. The complaint alleges that, throughout the Class Period, the Defendants misrepresented and/or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants’ false and misleading claims about Natera’s technology, the company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.

Positive

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)

2022-04-26 11:33:00

Natera, Inc. announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world, prospective, multi-center clinical study to assess the clinical utility of the Renasight™ genetic testing panel. The study has already enrolled 1,600 patients across 25 sites, representing leading academic and private nephrology clinics in the U.S., and will enroll up to 2,000 patients. It is expected to complete enrollment in the second quarter of 2022 with a publication expected to be submitted in late 2022. The study aims to demonstrate how genetic findings impact the management of patient care and examines diagnostic outcomes of patients tested with the Renasight genetic testing panel. In addition, the study will assess patient satisfaction, health knowledge and genetic literacy. All patients undergoing testing using the Renasight panel are offered optional pre- and post-test genetic information sessions with a genetic counselor in addition to their test results. Similarly, providers have access to Natera's genetic counselors for questions about the Renasight testing panel and review of test results.

Positive

Natera, Inc. Announces the Results of Large, Real-World Study Demonstrating High Yield Rate for Positive Genetic Findings with its Renasight Test in Patients with Chronic Kidney Disease

2022-04-19 11:33:00

Natera, Inc. announced the results of a large, real-world study demonstrating a high yield rate for positive genetic findings with its Renasight(TM) test in patients with chronic kidney disease (CKD). The study, published in the American Journal of Nephrology, reports on renal genetic testing results using Renasight to test for 382 genes associated with CKD on 1,007 unique patient samples that were ordered by general and transplant nephrologists for clinical purposes. Positive genetic findings were identified in 21.1% of cases, with a total of 220 positive results identified across 48 genes. In addition, the results also identified individuals with positive findings in more than one gene. The study concludes that Renasight, 'is highly effective in identifying monogenic variants underlying inherited kidney diseases and has utility for genetic diagnoses in the nephrology setting'. Renasight is a genetic test that uses next-generation sequencing (NGS) and other methodologies to identify germline genetic factors causing or contributing to kidney disease from a patient's blood or buccal sample. The test identifies certain autosomal dominant, autosomal recessive and X-linked disorders, including well-known risk alleles. Providers can use Renasight to identify a genetic predisposition, clarify a clinical diagnosis, or identify the etiology of an unknown kidney disease to help inform medical management. Additionally, genetic counseling and familial testing can be offered based on the test result.

Negative

Natera, Inc. Announces Resignation of Todd Cozzens as Member of Board, Effective May 25, 2022

2022-04-15 10:41:00

Natera, Inc. announced that on April 8, 2022, Todd Cozzens notified the Board of Directors of the Company of his intention to resign as a member of the Board and any committees of the Board, effective May 25, 2022.

Neutral

Natera, Inc. - Shareholder/Analyst Call

2022-04-13 20:00:00

2022 Annual Meeting of Stockholders

Positive

Natera, Inc. to Present Data from the Beatrice and I-Spy2 Trials in Early-Stage Tnbc and Hr+/Her2- Breast Cancer At the 2022 Aacr Annual Meeting

2022-04-11 11:33:00

Natera, Inc. announced that it will present new data relating to its tumor-informed molecular residual disease (MRD) test, Signatera™, at the annual meeting of the American Association for Cancer Research taking place April 8 – 13, 2022. Natera will have two data presentations in early-stage breast cancer, focused on patients that are high-risk hormone receptor-positive/HER2-negative (HR+/HER2-) and/or with triple negative breast cancer (TNBC). These data are the latest in a fast-growing body of evidence supporting the clinical use of Signatera MRD in breast cancer across all major subtypes. Details about the presentations are as follows: Abstract # 2796 | Poster Presentation | Date/time: Tuesday April 12, 9am-12:30pm: Tumor tissue and longitudinal plasma samples were collected post-surgery from 186 TNBC patients enrolled in the phase 3 BEATRICE clinical trial (NCT00528567) and analyzed using a research-use-only version of Natera's ctDNA technology. The results demonstrate that ctDNA status in samples collected post-surgery provided independent prognostic value beyond the known risk factors of lymph node involvement, tumor size and presence of tumor infiltrating lymphocytes. 19.9% of patients with early-stage TNBC were found to have detectable ctDNA after surgery, which was strongly associated with inferior outcomes (IDFS and OS), Lead time between first ctDNA positivity and radiographic recurrence was 6.1 months at the median, ranging up to 30.5 months. Abstract # 7878 | Poster Presentation | Date/time: Tuesday April 12, 9am-12:30pm: This study analyzed 734 blood samples collected serially during neoadjuvant chemotherapy (NAC) from 106 HR+/HER2- and 97 TNBC patients enrolled in the I-SPY2 trial, one of the large trials in the neoadjuvant setting. In TNBC, early clearance of ctDNA after just three weeks of treatment was a significant predictor of pathologic complete response, Patients who were ctDNA-negative after NAC, in both subtypes, showed significantly improved distant recurrence-free survival, even among those patients who did not achieve pathologic complete response.

Neutral

Natera, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022

2022-04-11 00:00:00

Natera, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 . Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Positive

Natera Publishes Valid Study Results for Prospera Lung Dd-Cfdna Transplant Rejection Assessment Test

2022-04-07 11:33:00

Natera, Inc. announced the publication of the VALID study1, showcasing its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection and allograft injury in lung transplant patients. The blinded prospective clinical validation, published in Transplant Direct, analyzed 195 biopsy-matched samples from 103 patients with cohort demographics that closely mirrored those reported to the Scientific Registry of Transplant Recipients (SRTR). Prospera Lung dd-cfDNA results were analyzed in connection with various complications from lung transplantation, including acute rejection (AR, includes both acute cellular rejection and antibody mediated rejection), chronic lung allograft dysfunction/neutrophilic-responsive allograft dysfunction (CLAD), and allograft infection (INFXN). The Prospera test exhibited outstanding performance data across all clinical events, including: AR vs. Stable; 0.91 AUC, AR+CLAD+INFXN vs. Stable; 0.76 AUC. The Prospera Lung test is already utilized in roughly 25% of U.S. lung transplant centers after its clinical launch in late 2021. Prospera is also being evaluated in a first of its kind clinical utility study, the multi-center randomized-controlled clinical trial, LAMBDA 001.

Negative

Natera, Inc. Announces Management Changes

2022-04-06 11:33:00

Natera, Inc.  announced Michael Olymbios, M.D., medical director of heart transplantation, and David Ross, M.D., medical director of lung transplantation.  Prior to joining Natera in 2020, Dr. Olymbios was at the Heart Transplant Program of Cedars-Sinai Medical Center in Los Angeles. Dr. Olymbios co-authored the international guidelines for the management of antibodies in heart transplantation as part of the International Society for Heart and Lung Transplantation (ISHLT). Prior to joining Natera in 2021, Dr. Ross served as medical director, lung transplantation at Ronald Reagan-UCLA Medical Center for 20 years and as a professor of medicine in the David Geffen School of Medicine at UCLA.

Positive

Natera, Inc. Announces Publication Highlighting Importance of Testing Total cfDNA When Monitoring Kidney Transplant Patients with COVID-19 Infection

2022-04-01 11:33:00

Natera, Inc. announced the results of a study1 to examine both total and donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients hospitalized with COVID-19 using its Prospera test to assess disease severity and risk of rejection. The study, published in Transplantation Proceedings, used the Prospera test to examine the relationship between total cfDNA and dd-cfDNA fraction when monitoring for rejection. The results indicate that high levels of total cfDNA, as can occur due to COVID-19 infection, result in a lower dd-cfDNA donor fraction and could inadvertently mask rejection when using donor fraction alone. The Prospera test identified two patients in the cohort with elevated total cfDNA and biopsy-proven rejection that would have otherwise gone undetected by dd-cfDNA donor fraction alone. Natera incorporated total cfDNA into the Prospera test in 2021, based on previous studies that showed combining analysis of dd-cfDNA and total cfDNA improved performance when evaluating transplant rejection.

Neutral

Blood Profiling Atlas in Cancer, BLOODPAC Summit 2022, Mar 31, 2022

2022-03-29 11:00:00

Blood Profiling Atlas in Cancer, BLOODPAC Summit 2022, Mar 31, 2022.

Neutral

Natera, Inc. Presents at BLOODPAC Summit 2022, Mar-31-2022

2022-03-29 11:00:00

Natera, Inc. Presents at BLOODPAC Summit 2022, Mar-31-2022 .

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Neutral

Natera, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-06-2022 08:30 AM

2022-02-04 15:50:00

Natera, Inc. Presents at SLAS 2022 International Conference and Exhibition, Feb-06-2022 08:30 AM. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States. Speakers: Ben Carvalho.

Neutral

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022

2022-01-13 18:45:00

American Association For Cancer Research, AACR Annual Meeting 2022, Apr 08, 2022 through Apr 14, 2022. Venue: Ernest N. Morial Convention Center, New Orleans, Louisiana, United States.

Neutral

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022

2021-12-28 18:17:00

Society for Laboratory Automation & Screening, SLAS 2022 International Conference and Exhibition, Feb 05, 2022 through Feb 09, 2022. Venue: Boston Convention and Exhibition Center, Boston, Massachusetts, United States.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Positive

Natera, Inc. Presents New Signatera™ MRD Data in Breast Cancer at SABCS 2021

2021-12-09 14:03:00

Natera, Inc. announced its new findings presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, from December 7, 2021 to December 10, 2021. The company is presenting two studies based on the use of Signatera in high-risk breast cancer patients. Detection of circulating tumor DNA post neoadjuvant chemotherapy using personalized assay is associated with disease relapse: in this study, Signatera was used for the detection and monitoring of ctDNA in 44 patients with early breast cancer across all major subtypes, before and after standard neoadjuvant chemotherapy, and then post-surgery with a median clinical follow up of 3 years. The study demonstrated that ctDNA status before surgery and at the last follow up were the strong predictors of patient outcomes after adjusting for all clinico-pathological risk factors such as stage, histology, tumor size and Ki67 status. Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery: this study assessed ctDNA status before surgery, after surgery prior to the start of adjuvant chemotherapy and after adjuvant chemotherapy, in 48 patients with early breast cancer across all major subtypes. ctDNA was detected in 29% of patients after surgery (prior to adjuvant treatment), including 20% in the ER-positive subgroup. Furthermore, results indicated that among patients who were ctDNA-positive after surgery, the majority benefited from adjuvant chemotherapy and did not relapse. Among patients who remained ctDNA-positive after adjuvant treatment, 100% relapsed. This data is new in a fast-growing body of evidence supporting the clinical use of Signatera in breast cancer, across all major subtypes in the neoadjuvant, adjuvant and metastatic settings. Signatera is also supporting multiple MRD-guided prospective clinical trials, where providers can refer eligible patients.

Neutral

Natera, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Natera, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Negative

Lieff Cabraser Files Negligence Lawsuit Against Natera, Inc. over Faulty Embryo Viability Testing

2021-11-19 15:18:00

The law firm of Lieff Cabraser Heimann & Bernstein, LLP, announced the filing of a lawsuit against Natera, Inc. alleging negligence, among other claims, over contaminated congenital defect tests that left families with no choice but to abandon what might well have been healthy, viable embryos. The Complaint notes that Natera’s failure to adequately control the quality of its embryo testing and the resulting loss of the costly and arduously and painfully obtained embryos led to devastating emotional damage for the subject families as well as the loss of precious embryos, time, and fertility options. Natera, Inc. is a clinical genetic testing company based in San Carlos, California that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Many of Natera’s client families rely on its Preimplantation Genetic Testing (PGT) to screen out embryos bearing known gene conditions as well as numerous other potential maladies. The success or failure of PGT testing has substantial emotional and psychological ramifications for those seeking to become parents. Losing the options to use embryos provokes fear, devastation, and despair. Many experience grief and anguish when fertility treatment does not result in pregnancy or when they lose fertility choices.For families who contract with Natera because their familial genes carry a heightened potential for disabling conditions, a “no-results” return on a PGT results in the embryos being wholly unusable, as there is no proof that the suspected and feared conditions are absent in the samples. Due to the rigors of the generation and testing process as well as inherent time constraints, victims lost any hope of using their embryos to have a child and had to start the grueling IVF process all over again. As the Complaint notes, plaintiffs relied on Natera’s printed and online representations that “the accuracy of Spectrum PGT-M testing is typically greater than 99%” such that their heightened concerns about possible genetic defects in their embryos could be allayed as Natera’s testing program guided them to finding healthy usable embryos for subsequent implantation. Had Natera disclosed that lapses in quality control were rendering entire sample sets useless, plaintiffs would never have risked losing sets of multiple precious and unique embryos by tying their success and viability to Natera’s testing. The Complaint observes that as a result of Natera’s grossly deficient performance of their role in the safe and secure testing of Plaintiffs’ embryo cells, Plaintiffs have suffered “foreseeable, serious, life-long harm, and lost the family-planning control that caused them to engage in PGT-M testing in the first place.” As a result of Defendants’ conduct, Plaintiffs suffered emotional trauma, including anxiety, hopelessness, fear, depression, devastation, and grief. Plaintiffs have been thrust into a state of panic about their futures and future family planning. As the Complaint further details, after Natera’s failure to safeguard and properly test Plaintiffs’ embryonic cells, Natera exacerbated Plaintiffs’ injuries by covering up its employees’ application of a defective chemical reagent to the relevant genetic material and by failing to communicate with clients in a proper manner. These failures include, but are not limited to: Failing to communicate with Plaintiffs about the chemical reagent failure in a timely manner, in that after Plaintiffs’ doctor informed Plaintiffs that the embryonic cells received a “no results” finding, Natera did not follow up to discuss the matter with Plaintiffs and forced Plaintiffs to reach out first; Failing to respond to Plaintiffs’ IVF doctor in a timely manner after Plaintiffs’ doctor reached out to Natera to inquire further about the testing failure and ultimately only providing minimal answers about the failure a week after Plaintiffs’ doctor first received the results; Informing Plaintiffs that Plaintiffs should feel “lucky” that Natera had refrained from involving their lawyers when offering to settle with clients; Telling Plaintiffs to feel grateful for Natera’s honesty, even in the face of Plaintiffs’ devastating loss; and Attempting to manipulate Plaintiffs into redoing the biopsy of the embryos, despite both the risks a second biopsy would pose to the embryos as well as Plaintiffs’ expressed discomfort in the face of those risks.

Positive

American Journal of Obstetrics and Gynecology Accepts Natera, Inc.'s First Manuscript from the Landmark Smart Study for Publication

2021-11-19 14:00:00

Natera, Inc. announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG). This publication describes the performance of the Panorama non-invasive prenatal test (NIPT) for common trisomies. SMART is the prospective NIPT study ever performed, and the only one to collect genetic confirmation of outcomes on all patients in the analysis. The study rigorously tested the performance of Panorama, confirming its market-leading performance in a real-world setting, and extending Panorama's position as the most thoroughly studied NIPT in the market. The study also included the validation of a new deep-learning, artificial intelligence-based algorithm for Panorama called Panorama AI, which utilizes information from over 2 million cfDNA tests performed by Natera. The SMART study enrolled more than 20,000 patients over five years at 21 U.S. and international sites. All patients received Panorama as part of routine clinical care. The key results in this initial publication include: Panorama demonstrated 99% sensitivity and >99.5% specificity for trisomy 21 in a real-world setting, consistent with previously published studies; and Panorama AI maintained high sensitivity, detected additional cases of common aneuploidies, and significantly lowered the no-call rate to 1.5%, and to 0.6% after one redraw.

Positive

Medicare Publishes Final Local Coverage Determination for Pan-Cancer Immunotherapy Monitoring with Natera's Signatera™ MRD Test

2021-11-11 16:52:00

Natera, Inc. announced that the CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using its Signatera molecular residual disease (MRD) test. An accompanying Billing and Coding Article, linked here, specifies that serial testing with Signatera is now covered for Medicare patients being treated with immunotherapy, regardless of tumor type. The final LCD is consistent with the draft posted in September 2020, also establishing an accelerated pathway to Signatera coverage in new testing indications.

Neutral

Natera, Inc. Provides Earnings Guidance for the Year 2021

2021-11-04 20:16:00

Natera, Inc. provided earnings guidance for the year 2021. For the year, the company anticipates 2021 total revenue of $615 million to $625 million.

Neutral

Natera, Inc., Q3 2021 Earnings Call, Nov 04, 2021

2021-10-28 12:33:00

Natera, Inc., Q3 2021 Earnings Call, Nov 04, 2021

Neutral

Natera, Inc. to Report Q3, 2021 Results on Nov 04, 2021

2021-10-28 12:33:00

Natera, Inc. announced that they will report Q3, 2021 results After-Market on Nov 04, 2021

Positive

Natera, Inc. Expands Organ Health Business With Commercial Launch of the Prospera Lung Transplant Assessment Test

2021-10-18 12:33:00

Natera, Inc. announced the launch and availability of its Prospera donor-derived cfDNA (dd-cfDNA) transplant assessment test for lung transplant recipients. The launch represents the latest addition to Natera's transplant monitoring portfolio beyond kidney and heart transplantation. Natera validated the Prospera Lung test in the VALID study, the large prospective trial of a commercial dd-cfDNA test for lung transplant assessment. The results, presented at CHEST 2021 and submitted for peer-reviewed publication, show the Prospera Lung test distinguishes antibody mediated and acute cellular rejection from stable patients with excellent performance, achieving an NPV of 97.33%, sensitivity of 89.06% and AUC of 0.91.1 The Prospera Lung test was also able to distinguish organ injury—including acute rejection, chronic rejection and infection (which can be more challenging)—from stable patients, with an AUC of 0.76. The gold standard of transbronchial biopsy (TBB) has several limitations including being invasive, costly and carrying the risk of complications. Natera is therefore launching LAMBDA 001, a randomized controlled trial to demonstrate non-inferiority for Prospera surveillance vs biopsy, as well as LAMBDA 002, an observational registry study to assess Prospera performance for detection of chronic lung allograft dysfunction (CLAD), the leading cause of mortality among lung transplant recipients.

Positive

Natera, Inc. Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management

2021-10-11 12:33:00

Natera, Inc. announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to assess tumor growth rates and predict patient survival in early-stage colorectal cancer (CRC). In previous studies, Signatera was validated to detect early-stage CRC recurrence 8.7 months earlier than CT imaging (median lead time), simply based on positive or negative MRD status. Without treatment, more than 98% of MRD-positive patients go on to relapse. This new study replicates that previous test performance in a larger, multi-center cohort; but it also demonstrates that MRD-positive patients can be further stratified based on the quantity of circulating tumor DNA (ctDNA) found in the blood, in particular, how quickly those levels grow over time (ctDNA growth rate, or ctDNA velocity). Every Signatera test report contains positive/negative MRD status as well as the mean number of tumor molecules observed per mL of plasma (MTM/mL). With serial testing, these quantities can be compared over time to calculate ctDNA velocity, a unique metric that Natera will make available to its customers. The publication describes a prospectively-collected, multicenter study of 168 stage III CRC patients undergoing curative intent treatment, with longitudinal MRD assessment before and after surgery, and then at regular intervals throughout adjuvant chemotherapy (ACT) and surveillance for up to 3 years (n=1204 samples). Key findings from the study include: Patients who remain MRD-positive after completion of ACT were highly likely to recur (HR 50.80), with a median lead time of 9.8 months ahead of radiographic recurrence, MRD-positive patients with slow-growing tumors (average 27% ctDNA-increase per month) experienced OS similar to those who did not relapse at all (3-year OS 100%); while patients with fast-growing tumors (average 137% increase per month) experienced poor outcomes with 3-year OS 37.5%, Persistent ctDNA clearance during and after ACT was strongly associated with good outcomes (100% 3-year RFS), while transient ctDNA clearance during ACT was associated with poor prognosis (0% 3-year RFS).

Positive

Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation

2021-10-06 12:33:00

Natera, Inc. announced the completion of the VALID Study (Validation for Allograft Lungs Implementing Donor-derived cell-free DNA) for Prospera™ in lung transplant recipients. The prospective study conducted by The Ohio State University (OSU) lung transplant program examined 204 plasma samples obtained with concurrent bronchoscopy biopsy procedures from 104 lung transplant recipients between September 2020 and June 2021. Using the Prospera Lung test, donor-derived cell-free DNA (dd-cfDNA) levels were compared across clinical-histopathologic diagnostic cohorts. During the study, 35 episodes of acute rejection were captured for analysis. This study represents the largest prospective trial of a commercial dd-cfDNA test for lung transplant assessment. The Prospera test leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for assessment of active rejection regardless of clinical presentation. It has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

Neutral

Volpara Health Technologies Limited to Collaborate with Natera, Inc

2021-09-29 23:27:00

Volpara Health Technologies Limited has entered into a collaboration agreement with Natera, Inc.to bring Natera's Empower Hereditary Cancer Test to Volpara's customers in the United States. Volpara will integrate Natera's Empower Hereditary Cancer Test into Volpara's software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings. At least one Volpara software product is used with over 33% of women who attend screening each year in the United States. Customers use Volpara's market-leading breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalised risk. Risk assessment is also required by many US insurance companies before additional testing. Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival.

Neutral

Natera, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 03:40 PM

2021-09-28 18:44:00

Natera, Inc. Presents at Longwood Healthcare Leaders Conference, Oct-05-2021 03:40 PM. Speakers: Paul R. Billings, Chief Medical Officer & Senior VP of Medical Affairs.

Neutral

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021

2021-09-28 13:09:00

Longwood Fund, Longwood Healthcare Leaders Conference, Oct 04, 2021 through Oct 05, 2021.

Positive

Natera, Inc. Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma

2021-09-17 12:33:00

Natera, Inc. announced new data being presented by the company and its collaborators on the use of the Signatera® personalized molecular residual disease (MRD) technology at the 2021 European Society for Medical Oncology (ESMO) Congress, taking place September 16–21, 2021. In three new studies, Natera will present the real-world clinical performance of Signatera in esophageal and gastric cancers, the power of ctDNA dynamics for assessing treatment response in uveal melanoma and the correlation of CHIP mutations with patient outcomes. This study used Signatera for the detection and quantification of ctDNA in a prospective real-world cohort of 886 plasma samples from 269 patients with gastroesophageal cancer. Serial time points were collected in a subset of patients to monitor ctDNA levels after curative intent therapy. Analysis showed tumor-informed ctDNA status is highly predictive of relapse in patients with stage I-IV disease, with ctDNA detected in 93.3% of samples at baseline. Uveal melanoma is a rare type of melanoma of the eye, associated with frequent liver metastases. This study of 127 mUM patients used a custom ctDNA assay for the evaluation of tebentasfusp therapy. Baseline ctDNA levels significantly correlated with tumor burden, and by week 9, 70% of evaluable patients showed ctDNA reduction associated with greater mean tumor shrinkage. For tebentafusp, ctDNA reduction appeared more correlated with overall survival than RECIST response. Buffy coat samples derived from 2484 patients diagnosed with colorectal, breast, lung and other solid cancers were analyzed for the presence of CHIP mutations, which were detected in 16% of patients, with the majority having a single mutation. As expected, the frequency of CHIP increased with age and reached 20% in patients above 60 years, who were also more likely to have multiple CHIP variants compared to the younger patients. Although CHIP mutations are not tumor-derived and should not be used to monitor MRD burden, the presence of CHIP in MRD-positive cases was associated with poor patient outcomes and reduced time to recurrence.

Neutral

Natera, Inc. has filed a Shelf Registration in the amount of $65.539914 million.

2021-09-10 00:00:00

Natera, Inc. has filed a Shelf Registration in the amount of $65.539914 million. Security Name: Common Stock Securities Offered: 545,893

Positive

Natera, Inc. Launches Prospera™ Kidney with Quantification to Further Improve Test Performance, Demonstrating Commitment to Innovation in Transplantation

2021-09-09 12:33:00

Natera, Inc. announced the launch of Prospera with Quantification, the only cfDNA test for kidney rejection that provides three values — the quantity of donor-derived cfDNA (dd-cfDNA), fraction of dd-cfDNA and total cfDNA on every report. Combining these three metrics has been shown to improve sensitivity when evaluating transplant rejection, compared to using dd-cfDNA fraction alone. Currently, other commercially available cfDNA tests that assess transplant rejection only report the fraction of dd-cfDNA. A recent peer-reviewed paper published in JASN1 showcased improved performance from Prospera with Quantification in 41 kidney transplant patients, 9 of whom had rejection. Incorporating the quantity of dd-cfDNA with the fraction of dd-cfDNA improved the sensitivity of the Prospera test from 7/9 to 9/9 in cases of active rejection, confirmed with renal biopsy. The clinical utility and increase in sensitivity have now been seen in six independent datasets, including in the large international, multi-site, prospective Trifecta study, which is expected to be published in early 2022. Prospera with Quantification is now commercially available through Natera's laboratory.

Neutral

Natera's Signatera Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer

2021-09-07 10:03:00

Natera, Inc. announced an agreement with NRG Oncology, a National Cancer Institute (NCI)-funded group, to use the Signatera personalized molecular residual disease (MRD) test in NRG-GI008: Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease (CIRCULATE-US), a prospective, multi-center, randomized clinical trial to investigate MRD-guided treatment strategies for patients with early stage colon cancer. The study will enroll approximately 2,000 patients with stage II or III colon cancer after resection. Patients identified as MRD-negative by Signatera will be randomized to receive either standard-of-care (SOC) adjuvant chemotherapy or observation unless circulating tumor DNA (ctDNA) is subsequently detected during surveillance. Patients identified as MRD-positive will be randomized to receive SOC chemotherapy or an intensified regimen with mFOLFIRINOX. The study's primary endpoint is to compare disease-free survival in (1) MRD-negative patients between immediate vs. delayed adjuvant chemotherapy, and (2) MRD-positive patients between SOC vs. intensified adjuvant chemotherapy. The CIRCULATE-US study is part of an international collaboration announced at the ESMO 2019 conference to tailor adjuvant chemotherapy using emerging ctDNA technologies. CIRCULATE-Japan, which also uses Signatera to drive adjuvant treatment escalation and de-escalation in patients with resected colon cancer, has already reported promising data at the ASCO and ESMO GI conferences this year.

Positive

Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test

2021-08-31 12:30:00

Natera, Inc. announced the validation and clinical availability of its Prospera Heart transplant assessment test for heart transplant recipients. This launch represents the first major application of the Prospera technology beyond kidney transplant and leverages Natera's expertise from performing greater than 3 million cfDNA tests worldwide. Prospera Heart delivers excellent performance with an area under the curve (AUC) of 0.844 from a single non-invasive test1, eliminating the need to combine two tests for each patient and thus reducing the cost to the health care system. Prospera Heart is easy to use – it does not require spinning down or shipment on dry ice. In addition to the multi-site validation study, Natera announced that Prospera Heart will be the donor-derived cfDNA (dd-cfDNA) test used in the landmark NIH-funded DTRT study – which is now fully enrolled. DTRT is a prospective, multi-center study that includes over 2,000 dd-cfDNA timepoints from roughly 175 heart transplant recipients who were followed for up to two years post-transplant. Natera expects the study to report results in early 2022.

Neutral

Natera, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021

2021-08-23 12:06:00

Natera, Inc. Presents at European Society for Medical Oncology Virtual Congress 2021, Sep-16-2021 . Venue: Paris Expo Porte de Versailles, Paris, France.

Neutral

Natera, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 11:45 AM

2021-08-10 13:03:00

Natera, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-13-2021 11:45 AM. Venue: New Windsor, United States. Speakers: Steve Chapman, CEO, President & Director.

Neutral

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021

2021-08-10 13:03:00

Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.

Neutral

Natera, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 03:45 PM

2021-08-10 13:03:00

Natera, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-15-2021 03:45 PM. Speakers: Steve Chapman, CEO, President & Director.

Neutral

Natera, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 08:30 AM

2021-08-07 06:43:00

Natera, Inc. Presents at Canaccord Genuity 41st Annual Growth Conference, Aug-11-2021 08:30 AM. Speakers: Michael Brophy, Chief Financial Officer.

Positive

Natera, Inc. Increases Earnings Guidance for the Full Year of 2021

2021-08-05 20:05:00

Natera, Inc. increased earnings guidance for the full year of 2021. For the year, the company increased revenue guidance from $550 million to $575 million range to $600 million to $620 million range.

Positive

Natera Announces Use of Signatera® as Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer

2021-08-04 13:03:00

Natera, Inc. announced that the first patient has been screened in a new phase III trial that uses its personalized, tumor-informed molecular residual disease test, Signatera, to identify early-stage breast cancer patients eligible for investigational treatment with GSK's PARP inhibitor niraparib (ZEJULA). The ZEST study, sponsored by GSK, is a randomized, multicenter, phase III, placebo-controlled clinical trial to evaluate the efficacy and safety of treatment with niraparib following surgery or completion of adjuvant therapy in 800 patients with either triple-negative breast cancer or HR-positive/HER2-negative, BRCA-mutated breast cancer. After definitive upfront treatment, serial testing with Signatera will be used to identify patients who have detectable MRD to evaluate therapy with niraparib versus placebo in a setting where relapse is detected early ahead of radiologically defined disease progression. This is the second phase III registrational trial to incorporate Signatera as a companion diagnostic. Signatera has been designated as a Breakthrough Device by the FDA for three different clinical indications, including one designation for the early-stage breast cancer intended use being evaluated in the ZEST trial.

Neutral

Natera, Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-29 13:03:00

Natera, Inc., Q2 2021 Earnings Call, Aug 05, 2021

Neutral

Natera, Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-29 13:03:00

Natera, Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021

Positive

Natera,Inc Announces New Peer-Reviewed Paper Published in Gastroenterology Validating its Personalized and Tumor-Informed Molecular Residual Disease Assay, Signatera, in Resected Esophageal Adenocarcinoma

2021-07-28 13:03:00

Natera,Inc announced a new peer-reviewed paper published in Gastroenterology validating its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, in resected esophageal adenocarcinoma (EAC). The study represents the first published data on the use of Signatera in EAC and demonstrates the potential of the Signatera technology in esophageal cancer, which sees around 20,000 new cases per year in the U.S. Key findings from this retrospective study of 20 EAC patients after resection: Signatera detected recurrence with a sensitivity of 80% (4/5). The only missed recurrence had the last sample drawn two years before recurrence. The specificity was 100% (12/12) and the PPV was 100%. Signatera detected recurrence with a median lead time of almost one year before clinical or radiological recurrence. Postsurgical MRD-positive patients had disease-free survival of 14.2 months, compared to 51.2 months in MRD-negative patients, indicating prognostic value in this setting. Patients who were MRD-positive preoperatively and became MRD-negative after surgery had a good prognosis, indicating that Signatera can potentially be used to risk-stratify patients for adjuvant therapy.

Neutral

Natera, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 11:20 AM

2021-07-22 14:24:00

Natera, Inc. Presents at Wells Fargo 2021 Virtual Healthcare Conference, Sep-10-2021 11:20 AM. Speakers: Michael Brophy, Chief Financial Officer.

Neutral

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021

2021-07-22 09:08:00

Wells Fargo Securities, LLC, Wells Fargo 2021 Virtual Healthcare Conference, Sep 09, 2021 through Sep 10, 2021.

Negative

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $508.5 million.

2021-07-21 00:00:00

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $508.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 4,500,000 Price\Range: $113 Discount Per Security: $6.4975

Negative

Certain Common Stock of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021.

2021-07-21 00:00:00

Certain Common Stock of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Common Stock will be under lockup for 61 days starting from 21-JUL-2021 to 20-SEP-2021. Details: The company’s directors and executive officers, during the period ending 60 days after the date of this prospectus, (the "restricted period"), have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or publicly disclose the intention to engage in any such transaction; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock.

Negative

Certain Options of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021.

2021-07-21 00:00:00

Certain Options of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Options will be under lockup for 61 days starting from 21-JUL-2021 to 20-SEP-2021. Details: The company’s directors and executive officers, during the period ending 60 days after the date of this prospectus, (the "restricted period"), have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or publicly disclose the intention to engage in any such transaction; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock.

Negative

Certain Restricted Stock Units of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021.

2021-07-21 00:00:00

Certain Restricted Stock Units of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2021. These Restricted Stock Units will be under lockup for 61 days starting from 21-JUL-2021 to 20-SEP-2021. Details: The company’s directors and executive officers, during the period ending 60 days after the date of this prospectus, (the "restricted period"), have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock or publicly disclose the intention to engage in any such transaction; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock.

Negative

Natera, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

2021-07-20 00:00:00

Natera, Inc. has filed a Follow-on Equity Offering in the amount of $350 million. Security Name: Common Stock Security Type: Common Stock

Neutral

Natera, Inc. Provides Preliminary Earnings Guidance for the Second Quarter Ended June 30, 2021

2021-07-19 12:46:00

Natera, Inc. provided preliminary earnings guidance for the second quarter ended June 30, 2021. Total revenues for the second quarter of 2021 are expected to be approximately $138 million to $141 million, compared with total revenues of $86.5 million for the second quarter of 2020, which represents approximately 60% year on year growth. The company expects to recognize a loss from operations of approximately $113 million to $117 million for the second quarter of 2021, compared to a loss from operations of $51.7 million for the second quarter of 2020, reflecting the company's increased research and development and selling, general and administrative costs in support of the commercialization of its new product offerings, which are expected to continue in subsequent quarters.

Positive

Natera, Inc. Presents New Data on Personalized and Tumor-Informed Molecular Residual Disease (MRD) Assay

2021-07-02 15:00:00

Natera, Inc. announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO GI), taking place June 30 - July 3, 2021. Data will be presented in colorectal cancer (CRC) and pancreatic cancer. Natera will present updated results from the prospective, multi-center, randomized CIRCULATE-Japan trial, the large MRD-guided study to date in CRC, designed to investigate ctDNA-guided treatment strategies for patients with stage I-IV resected CRC. With follow-up information now available in the first 808 patients in this trial, this readout is multiple times larger than any previous Natera MRD study in CRC, and as such, creates a new benchmark for evaluating test performance.

Fundamental Summary

The financials published by Natera for Q1 were weak and discouraging. Their growth, value, and income factors indicate a poor execution and strategy, which isn't generating exciting growth. These results indicate a weak growth potential for Natera's stock's price moving forward. As such, Natera received an overall score of 47 and a UNDERPERFORM recommendation.

Natera reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 194.13 million compared to USD 152.32 million a year ago. Net loss was USD 138.6 million compared to USD 63.85 million a year ago. Basic loss per share from continuing operations was USD 1.45 compared to USD 0.74 a year ago. Diluted loss per share from continuing operations was USD 1.45 compared to USD 0.74 a year ago.

Business Description

Natera, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera in 2012. Natera was founded in 2003 and is based in Austin, Texas.

Sector Overview

Natera is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Natera's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,144.7 -7.4% 65
Liabilities 602.3 3.3% 73
Price to Book 7.0 -48.2% 42
Cash & Equivalents 158.3 87.6% 95
Equity 542.3 -17.0% 43
EBITDA -520.2 -16.3% 51
Total Revenues 667.3 6.7% 52
Parameter Value Change Score
Return on Equity -119.5 -44.3% 78
Net Cashflow 93.2 160.7% 52
Capital Expenditure -55.2 -11.3% 56
Asset Turnover 0.7 13.5% 84
Free Cashflow -4.9 -14.9% 54

* All values are TTM

The below chart reflects Natera's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Natera's peer average final assessment score stands on 57.0, Natera's score is 47.

  •  NTRA
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 21 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 22 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 23 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 25 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 27 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 29 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 30 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 31 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 32 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 35 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 36 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 37 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 38 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 39 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 40 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 41 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 42 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 43 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 45 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 46 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 47 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Natera's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Natera's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.

Bearish 52
Close Price 37.72
52W Low 28.13
52W High 126.36
5D MA 38.63
50D MA 36.07
200D MA 71.25
MACD 0.37
RSI 58.65
STOCH 62.23

Balance Sheet Analysis

Natera's recently published balance sheet conveys disappointing growth, particularly with respect to Book Value Factors and Equity metrics. Natera publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 7.0 and represents -48.2% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Disappointing results in book value factors typically precede negative pressure in stock prices, so its book value factors received a grade of 42. Also, Natera reported weak equity changes momentum this period. At filing, equity was reported as 542.3, representing -17.0% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Consequently, their equity movement received a grade of 43. That said, one metric, Cash & Equivalents, stood out as strongly positive. Natera did a great job related to cash and cash equivalents this period, which stood at 158.3, representing a 87.6% change from the previous filing. This impressive growth, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. Consequently, their cash and cash equivalents movement received a grade of 95. Therefore, it received a cautionary score of 54.

Parameter Value Change Score
Assets 1,144.7 -7.4% 65
Liabilities 602.3 3.3% 73
Price to Book 7.0 -48.2% 42
Cash & Equivalents 158.3 87.6% 95
Equity 542.3 -17.0% 43
* All values are TTM

The below chart describes Natera's performance as reflected on its balance sheet with respect to its peers. While Natera received a balance sheet score of 54, the average of its peers stands on 62.0.

  •  NTRA
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 21 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 22 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 23 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 25 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 27 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 28 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 29 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 30 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 31 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 32 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 33 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 35 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 36 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 37 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 38 1
Geron Corporation 566.2M 69 72 37 59 62 60 39 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 40 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 41 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 42 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 43 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 45 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 46 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 47 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Natera's most recent income statement report was not encouraging. Natera's EBIDTA now sits at -520.2 and represents -16.3% change from the last reporting period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Therefore, their EBITDA component earned a score of 51. Also, Natera's revenue efficiency metrics look especially concerning this period, highlighting issues management is having controlling and reducing expenses while increasing earnings. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Its uninspiring revenue efficiency is even more concerning relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 52. On the other hand, Return Factors, jumped out as looking rather positive. In this filing, Natera reported a return on equity (ROE) ratio of -119.5, which represents a change of -44.3%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 78. Therefore, its income statement earned a grade of 52.

Parameter Value Change Score
EBITDA -520.2 -16.3% 51
Total Revenues 667.3 6.7% 52
Return on Equity -119.5 -44.3% 78
* All values are TTM

The below chart describes Natera's performance as reflected on its income statement with respect to its peers. While Natera received a income statement score of 52 , the average of its peers stands on 56.0.

  •  NTRA
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 21 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 22 1
Insmed Incorporated 2.4B 51 58 73 57 23 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 25 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 27 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 28 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 29 1
IVERIC bio, Inc. 1.1B 84 58 79 70 30 1
FibroGen, Inc. 1.0B 48 74 63 67 31 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 32 1
ImmunoGen, Inc. 946.1M 40 73 71 64 33 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 35 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 36 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 37 1
AnaptysBio, Inc. 586.3M 97 50 77 68 38 1
Geron Corporation 566.2M 89 67 73 78 39 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 40 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 41 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 42 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 43 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 45 1
Precigen, Inc. 299.1M 57 87 59 79 46 1
bluebird bio, Inc. 288.7M 99 91 61 96 47 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Natera's most recent cash flow report was not encouraging. Natera's net cash flow metrics were 93.2 according to their current filing, which represents a 160.7% change from the previous report. Their net cash flow momentum should be a cause for concern and could bring negative momentum for Natera's stock price going forward. Hence, their net cash flow earned a score of 52. Also, Natera's published free cash flow numbers were subpar and could mean that management has lost focus on achieving healthy growth. Natera recorded free cash flow of -4.9, which represents -14.9% growth from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Consequently, their free cash flow movement received a grade of 54. On the other hand, Asset Turnover, jumped out as looking rather positive. Natera is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.7, representing a 13.5% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. The company's asset turnover movement, therefore, received a grade of 84. Therefore, its cash flow earned a grade of 58.

Parameter Value Change Score
Net Cashflow 93.2 160.7% 52
Capital Expenditure -55.2 -11.3% 56
Asset Turnover 0.7 13.5% 84
Free Cashflow -4.9 -14.9% 54
* All values are TTM

The below chart describes Natera's performance as reflected on its cash flow with respect to its peers. While Natera received a cash flow score of 58, the average of its peers stands on 63.0.

  •  NTRA
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 21 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 22 1
Insmed Incorporated 2.4B 79 80 61 89 82 23 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 24 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 25 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 26 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 27 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 28 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 29 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 30 1
FibroGen, Inc. 1.0B 86 74 48 87 84 31 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 32 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 33 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 34 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 35 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 36 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 37 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 38 1
Geron Corporation 566.2M 78 68 49 81 77 39 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 40 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 41 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 42 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 43 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 44 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 45 1
Precigen, Inc. 299.1M 82 75 37 85 74 46 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 47 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.